2nd Circ. Revives Pfizer Securities Suit Over Drug Risks

Law360, New York (April 12, 2016, 11:04 AM EDT) -- The Second Circuit on Tuesday revived a securities class action against Pfizer over the alleged hidden health risks of two of its drugs, saying the lower court had improperly excluded an expert who was set to testify on behalf of the plaintiffs and had earlier erred when it granted the drugmaker summary judgment.

In a 63-page opinion remanding the case for further proceedings, the New York federal appeals court said District Judge Laura Taylor Swain's overstepped when she barred a plaintiff expert from testifying at a scheduled 2014 trial on loss causation and damages associated with Pfizer Inc.'s alleged misrepresentations about...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!